ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
The research will be presented during the poster session of the
symposium by the first author of the abstract, Dr.
The findings from the preclinical studies demonstrate that ERY-MET,
which is methionine gamma-lyase-encapsulated in red blood cells (
Abstract #78: Methionine gamma-lyase-encapsulated into red blood cells (ERY-MET) shows profound antitumor activity in gastric carcinoma
Author: | Vanessa Bourgeaux | |
Date: | Thursday, January 19, 2017 | |
Time: | 12:30 – 2:00 p.m. PST | |
5:30 – 7:00 p.m. PST | ||
Location: | Board G12, Moscone West Building | |
Poster Session: | A: Cancers of the Esophagus and Stomach |
Methionine is an essential amino acid, which all cells need to grow and
multiply. More particularly, fast-growing tumor cells exhibit very high
requirements of methionine to proliferate. The enzyme methionine
gamma-lyase (MGL) mediates tumor starvation via systemic lowering of
methionine levels. MGL is an enzyme with a short half-life and is
dependent on a co-factor, a Vitamin B6 derivative, to function.
Encapsulating MGL in RBCs extends the half-life significantly and the
conversion of Vitamin B6 to the co-factor happens naturally inside the
The Company’s research team determined the plasma methionine level reduction as a pharmacodynamics biomarker and analyzed the anti-tumor activity of weekly ERY-MET injections in mice. The study found that ERY-MET, in combination with daily Vitamin B6 supplementation, increased active MGL half-life in vivo, from less than 24 hours to 8-9 days. The combined ERY-MET and Vitamin B6 treatment exhibited anti-tumor activity in 100% of treated mice, with tumor growth inhibitions varying from 91% to 100% by the end of the study.
Dr. Bourgeaux stated, “We had already identified the potential of ERY-MET as a tumor starvation agent in a mouse model of glioblastoma. This work, demonstrating that ERY-MET can also induce tumor growth inhibition in mice with human gastric adenocarcinoma and achieving an almost complete regression, strengthens the Company’s current strategy to develop product candidates based upon its proprietary ERYCAPS platform as potential treatments for various oncology indications in addition to blood cancers. We believe ERY-MET shows significant promise as a new anti-tumor drug to treat gastric and other recalcitrant cancers.”
About ERYTECH: www.erytech.com
Founded in
Eryaspase consists of an enzyme, L-asparaginase, encapsulated inside
donor-derived red blood cells. L-asparaginase depletes asparagine, a
naturally occurring amino acid essential for the survival and
proliferation of cancer cells, from circulating blood plasma. ERYTECH
produces eryaspase at its own GMP-approved and operational manufacturing
site in
In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to induce tumor starvation. The company is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies and enzyme replacement therapies.
ERYTECH is listed on
Forward-looking information
This press release contains forward-looking statements, forecasts and
estimates with respect to the clinical development plans, business and
regulatory strategy, and anticipated future performance of ERYTECH and
of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar
expressions. They include all matters that are not historical facts.
Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may
not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond ERYTECH's control. There can be no
guarantees with respect to pipeline product candidates that the
candidates will receive the necessary regulatory approvals or that they
will prove to be commercially successful. Therefore, actual results may
turn out to be materially different from the anticipated future results,
performance or achievements expressed or implied by such statements,
forecasts and estimates. Documents filed by
View source version on businesswire.com: http://www.businesswire.com/news/home/20170117005964/en/
Source:
ERYTECH
Gil Beyen
Chairman and CEO
or
Eric
Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
or
The
Ruth Group
Investor relations
Lee Roth, +1 646 536
7012
lroth@theruthgroup.com
or
Media
relations
Kirsten Thomas, +1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien
Perez
Investor relations
or
Nicolas Merigeau
Media
relations
+33 1 44 71 98 52
erytech@newcap.eu